July 31, 2018 – By Ira Colvard
Chemocentryx Inc (NASDAQ:CCXI) had a decrease of 2.85% in short interest. CCXI’s SI was 2.45 million shares in July as released by FINRA. Its down 2.85% from 2.52M shares previously. With 277,400 avg volume, 9 days are for Chemocentryx Inc (NASDAQ:CCXI)’s short sellers to cover CCXI’s short positions. The SI to Chemocentryx Inc’s float is 11.45%. The stock decreased 2.29% or $0.26 during the last trading session, reaching $11.11. About 146,973 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since July 31, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9
Analysts expect Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report $-0.46 EPS on August, 1.They anticipate $0.04 EPS change or 8.00% from last quarter’s $-0.5 EPS. After having $-0.63 EPS previously, Momenta Pharmaceuticals, Inc.’s analysts see -26.98% EPS growth. The stock decreased 0.69% or $0.2 during the last trading session, reaching $28.75. About 419,901 shares traded. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 53.67% since July 31, 2017 and is uptrending. It has outperformed by 41.10% the S&P500. Some Historical MNTA News: 08/05/2018 – Momenta Evaluating Options, Including Sale of One or More Biosimilar Assets; 19/04/2018 – DJ Momenta Pharmaceuticals Inc, Inst Holders, 1Q 2018 (MNTA); 21/03/2018 – Amphastar: Ruled ‘Prevailing Party’ in Patent Litigation Against Momenta Pharmaceuticals and Sandoz; 21/03/2018 Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc; 08/05/2018 – MOMENTA SEES FY OPER EXPENSES $180.0M TO $220.0M; 08/05/2018 – MOMENTA PHARMACEUTICALS INC MNTA.O : JP MORGAN RAISES TARGET PRICE TO $23 FROM $18; 21/03/2018 – Amphastar: District Court Also Denied Momenta’s and Sandoz’s Motion to Dismiss Amphastar’s Antitrust Lawsuit; 17/05/2018 – Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity; 21/03/2018 – AMPHASTAR SAYS COURT DENIED MOMENTA, SANDOZ MOTION TO DISMISS; 08/05/2018 – Momenta 1Q Loss $47.6M
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $546.06 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 38.31 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
Since May 1, 2018, it had 0 insider purchases, and 12 insider sales for $7.89 million activity. Schall Thomas J. also sold $2.36M worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shares. Cappel Markus J. sold $344,201 worth of stock. $1.34 million worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by KANAYA SUSAN M on Tuesday, June 26.
Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It turned negative, as 10 investors sold ChemoCentryx, Inc. shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Trexquant Inv Ltd Partnership holds 11,574 shares. California State Teachers Retirement System owns 38,188 shares or 0% of their US portfolio. Pub Employees Retirement Of Ohio holds 117,524 shares or 0.01% of its portfolio. Fernwood Invest Mgmt Ltd Liability Corp accumulated 0.08% or 10,000 shares. Moreover, Td Asset Management has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Jacobs Levy Equity has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Moreover, Strs Ohio has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 55,500 shares. Alliancebernstein L P holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 40,100 shares. American Group Inc invested in 15,795 shares. Spark Inv Mgmt Ltd Company reported 62,600 shares. Daiwa Secs Grp Inc has 269 shares. Millennium Management Ltd Liability Corp reported 324,112 shares. American Century Companies Incorporated invested in 31,279 shares. 2.38M are held by Wasatch Advsrs Inc. Landscape Cap Llc accumulated 0.02% or 24,145 shares.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since March 13, 2018 according to SRatingsIntel. JP Morgan maintained it with “Overweight” rating and $16 target in Tuesday, March 13 report.
Since February 12, 2018, it had 0 insider buys, and 33 selling transactions for $6.43 million activity. $8,516 worth of stock was sold by Leicher Bruce on Tuesday, May 8. $60,216 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by Storer Scott M on Monday, February 12. On Monday, February 12 WHEELER CRAIG A sold $301,050 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) or 18,648 shares. On Thursday, May 10 the insider KWON YOUNG sold $7,726. Stoner Elizabeth also sold $102,626 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares. $7,726 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares were sold by Kaundinya Ganesh Venkataraman. Shares for $49,321 were sold by GILMAN STEVEN C.
More news for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were recently published by: Benzinga.com, which released: “Benzinga’s Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut” on July 19, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering” and published on July 13, 2018 is yet another important article.
Among 2 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Momenta Pharmaceuticals had 2 analyst reports since February 22, 2018 according to SRatingsIntel. Cantor Fitzgerald initiated the stock with “Hold” rating in Monday, June 11 report. Stifel Nicolaus upgraded Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Thursday, February 22 to “Buy” rating.
Investors sentiment decreased to 1.1 in Q1 2018. Its down 0.35, from 1.45 in 2017Q4. It turned negative, as 22 investors sold Momenta Pharmaceuticals, Inc. shares while 45 reduced holdings. 25 funds opened positions while 49 raised stakes. 72.00 million shares or 0.05% more from 71.96 million shares in 2017Q4 were reported. Amer Century has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Reilly Financial Advisors Limited Liability Corporation has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 1,000 shares. Citigroup Inc holds 0% or 65,184 shares. Millennium Mgmt Llc holds 0.02% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 669,149 shares. The Connecticut-based Quantitative Systematic Strategies Limited Liability Company has invested 0.05% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). State Street has invested 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Tci Wealth Inc has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). First Personal Financial Ser accumulated 1,074 shares or 0% of the stock. Guggenheim Lc has invested 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Rock Springs Mngmt L P has invested 0.27% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Jacobs Levy Equity Management reported 0.07% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Schwab Charles Invest Management stated it has 389,152 shares. Wellington Mgmt Group Llp invested in 0.04% or 8.89M shares. 684,810 are held by Ameriprise Financial Inc. Northern Trust Corporation invested in 922,744 shares.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company has market cap of $2.22 billion. The company??s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. It currently has negative earnings. The Company’s biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn’s disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.